Neuropathic Pain Market, by Drug Class (Tricyclic Anti-Depressant, Anticonvulsant, Local Anaesthesia, Opioids, Steroids, Others), By Indication (Diabetic neuropathy, Chemotherapy-induced Peripheral neuropathy and Others), By Distribution Channel (Retail P

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	168 Pages	Coherent Market Insights	March, 2025	CMI20007647

Best Price Guarantee
Price	from $4,500
Length	168 Pages
Publisher	Coherent Market Insights
Published Date	March, 2025
SKU	CMI20007647

Neuropathic pain is a condition which involves pain caused due to damage or diseases affecting the nervous system. These conditions may include diseases such as diabetes causing diabetic neuropathy, chemotherapy induced neuropathic pain, and trigeminal neuralgia. Diabetic neuropathy is the damage caused to the nerve due to diabetes, which often leads to pain and numbness in feet or lower legs. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy. There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy. According to data published on Up to Date journal on December 2022, an estimated 50% of diabetic population suffers from diabetic neuropathy across the globe. Further, as per CDC estimates, 6-7 people per 1000 diabetic population suffer from diabetic neuropathy in the U.S.

Market Dynamics

The key market players are focusing on adoption of growth strategies such as research and development activities, clinical trials, acquisitions and launch of newer products, which is attributed to the growth of global neuropathic pain market. For instance, on November 16, 2021, Francesco Bono a university started phase 2 study of BoNT-A for the neurogenic inflammation and neuropathic pain. The drug is under the clinical trial in phase 2, study starts on May 25, 2030 and expected to complete by December 2023.

Key features of the study:

This report provides an in-depth analysis of the global neuropathic pain market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neuropathic pain market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., Eily Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Squibb, Baxter Healthcare Corporation, and Depomed, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global neuropathic pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuropathic pain market.

Detailed Segmentation:

Global Neuropathic Pain Market, By Drug Class:
Tricyclic Anti-Depressant
Anticonvulsant
Local Anaesthesia
Opioids
Steroids
Others
Global Neuropathic Pain Market, By Indication:
Diabetic neuropathy
Chemotherapy-induced Peripheral neuropathy
Other
Global Neuropathic Pain Market, By Distribution Channel:
Retail Pharmacies
Drug Store
Online Pharmacies
Global Neuropathic Pain Market, By Geography:
North America
U.S.
Canada
Europe
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
GCC
Israel
Rest of Middle East
Africa
Central Africa
South Africa
North Africa
Company Profiles
Pfizer, Inc.
Johnson & Johnson Services, Inc.
Sanofi S.A.
Eily Lily and Company
GlaxoSmithKline PLC
Biogen Idec.
Bristol-Myers Squibb
Baxter Healthcare Corporation
Depomed, Inc.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Drug Class; Market Snapshot, By Indication; Market Snapshot, By Distribution Channel; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Recent Product Launches; Epidemiology; Merger, Acquisition, and Collaborations; Regulatory Scenario; Key Developments; PEST Analysis
4. Global Neuropathic Pain Market – COVID-19 Impact Analysis: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global Neuropathic Pain Market , By Drug Class, 2020 – 2032, (US$ Billion): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021–2032; Segment Trends; Tricyclic Anti-Depressant; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn); Anticonvulsant; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn); Local Anesthesia; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn); Opoids; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn); Steroids; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
6. Global Neuropathic Pain Market, By Indication, 2020 – 2032, (US$ Billion): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021–2032; Segment Trends; Diabetic Neuropathic; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn); Sports Injuries; Trauma cases; Chemotherapy-induced Peripheral Neuropathic; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn); Osteoarthritis; Osteoporosis; Prolapsed Disc; Degenerative Joint Diseases; Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
7. Global Neuropathic Pain Market, By Distribution Channel, 2020 – 2032, (US$ Billion): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021–2032; Segment Trends; Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn); Drug Store; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
8. Global Neuropathic Pain Market, By Region, 2020 – 2032, (US$ Billion): Introduction; Market Share Analysis, By Region, 2025 and 2032 (%); Y-o-Y Growth Analysis, For Regions, 2021–2032; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Billion); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Indication , 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Billion); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Indication , 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Billion); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Indication , 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Billion); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Indication , 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Billion); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Indication , 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Billion); GCC; North Africa; Central Africa; South Africa
9. Competitive Landscape: Pfizer,Inc; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Johnson & Johnson Services, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Sanofi S.A.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Eily Lily and Company; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; GlaxoSmithKline PLC Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Biogen Idec.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Bristol-Myers Squibb; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Baxter Healthcare Corporation; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Depomed, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies
10. Section: Research Methodology; About Us; *Browse 35 market data tables and 33 figures on “Global Neuropathic Pain Market” - Global forecast to 2032